Journey Medical Corporation Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

NET LOSS PER COMMON SHARE

NET LOSS PER COMMON SHARE

6 Months Ended

Jun. 30, 2026

NOTE 17. NET LOSS PER COMMON SHARE

The Company accounts for and discloses net earnings (loss) per share using the treasury stock method. Net earnings (loss) per share, or basic earnings (loss) per share, is computed by dividing net earnings (loss) by the weighted-average number of shares of common stock outstanding. Net earnings (loss) per share assuming dilutions, or diluted earnings (loss) per share, is computed by reflecting the potential dilution from the exercise of in-the-money stock options and the issuance of non-vested restricted stock units.

The Company’s basic and diluted weighted-average number of common shares outstanding for the three and six-month periods ended June 30, 2026 and 2025 were as follows:

Three-Month Periods Ended June 30,

Six-Month Periods Ended June 30,

 

2026

 

2025

 

2026

 

2025

Basic and diluted

27,493,693

23,290,806

27,399,881

22,952,801

Potentially dilutive securities:

Unvested restricted stock units

1,847,931

2,363,891

1,847,931

2,363,891

Stock options

573,995

1,981,652

639,925

1,925,258

Total potentially dilutive securities

2,421,926

4,345,543

2,487,856

4,289,149

The Company’s potentially dilutive securities, including unvested restricted stock and options have been excluded from the computation of diluted loss per share for the three and six-month periods ended June 30, 2026, and 2025, as the effect would be to reduce the loss per share. Therefore, the weighted average common stock outstanding used to calculate both basic and diluted income loss per share is the same for the three and six-month periods ended June 30, 2026 and 2025.